Identification
- Generic Name
- Sodium feredetate
- DrugBank Accession Number
- DB13381
- Background
-
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
- Weight
-
Average: 367.047
Monoisotopic: 366.984071 - Chemical Formula
- C10H12FeN2NaO8
- Synonyms
-
- Feredato de sodio
- Ferédétate de sodium
- Ferric sodium EDTA
- Ferric sodium ethylenediaminetetraacetate
- Ferrostrane
- Ferrostrene
- Monosodium ferric EDTA
- Natrii feredetas
- Sodium feredetate
- Sodium ferric EDTA
- Sodium iron EDTA
- Sodium ironedetate
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
-
Not Available
- Mechanism of action
- Not Available
- Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Sodium feredetate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Almasilate Almasilate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Asenapine Asenapine can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium carbonate Calcium carbonate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium Phosphate Sodium feredetate can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium phosphate dihydrate Sodium feredetate can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Carbidopa Sodium feredetate can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy. Cefdinir Sodium feredetate can cause a decrease in the absorption of Cefdinir resulting in a reduced serum concentration and potentially a decrease in efficacy. Identify potential medication risks很容易比较are up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
-
- Avoid milk and dairy products.
- Avoid multivalent ions.
- Limit caffeine intake. Food and beverages containing caffeine may reduce iron absorption.
- Take separate from antacids.
- Take with foods containing vitamin C. Foods rich in vitamin C increase the absorption of iron.
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Active Moieties
-
Name Kind UNII CAS InChI Key Iron unknown E1UOL152H7 7439-89-6 XEEYBQQBJWHFJM-UHFFFAOYSA-N Ferric cation ionic 91O4LML611 20074-52-6 VTLYFUHAOXGGBS-UHFFFAOYSA-N - International/Other Brands
- Calmosine/Sytron
- Unapproved/Other Products
-
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Bal-Care DHA Sodium feredetate(25.65 mg/1)+Ascorbic acid(120 mg/1)+Beta carotene(2850 iU / 1)+Calcium carbonate(219 mg/1)+Cholecalciferol(840 [iU]/1)+Cupric oxide(2 mg/1)+Cyanocobalamin(.012 mg/1)+DL-alpha tocopheryl acetate(3 mg/1)+Folic acid(1 mg/1)+Iodine(.223 mg/1)+Iron sucrose(1.35 mg/1)+氧化镁(25 mg/1)+Nicotinamide(20 mg/1)+Omega-3 fatty acids(430 mg/1)+Pyridoxine hydrochloride(50 mg/1)+Riboflavin(4 mg/1)+Thiamine mononitrate(1.8 mg/1)+Zinc oxide(25 mg/1) Kit Oral Pru Gen Pharmaceuticals 2012-05-01 Not applicable 我们 Bal-Care DHA Essential Sodium feredetate(25.65 mg/1)+Ascorbic acid(120 mg/1)+Beta carotene(2850 iU / 1)+Calcium carbonate(219 mg/1)+Cholecalciferol(840 [iU]/1)+Cupric oxide(2 mg/1)+Cyanocobalamin(.012 mg/1)+DL-alpha tocopheryl acetate(3 mg/1)+Folic acid(1 mg/1)+Iodine(.223 mg/1)+Iron sucrose(1.35 mg/1)+氧化镁(25 mg/1)+Nicotinamide(20 mg/1)+Omega-3 fatty acids(374 mg/1)+Pyridoxine hydrochloride(50 mg/1)+Riboflavin(4 mg/1)+Thiamine mononitrate(1.8 mg/1)+Zinc oxide(25 mg/1) Kit Oral Pru Gen Pharmaceuticals 2012-05-01 Not applicable 我们 Cavan-EC SOD DHA Sodium feredetate(30 mg/1)+Ascorbic acid(130 mg/1)+Beta carotene(3000 [iU]/1)+Calcium(230 mg/1)+Cholecalciferol(410 [iU]/1)+Copper(2 mg/1)+Cyanocobalamin(12 ug/1)+Folic acid(1 mg/1)+镁(25 mg/1)+Nicotinamide(20 mg/1)+Omega-3 fatty acids(440 mg/1)+Pyridoxine hydrochloride(28 mg/1)+Riboflavin(4 mg/1)+Thiamine mononitrate(1.8 mg/1)+Vitamin E(30 mg/1)+Zinc(26 mg/1) Kit Oral Seton Pharmaceuticals 2010-01-10 2014-07-15 我们 Cavan-EC SOD DHA Sodium feredetate(30 mg/1)+Ascorbic acid(130 mg/1)+Beta carotene(3000 [iU]/1)+Calcium carbonate(230 mg/1)+Cholecalciferol(410 [iU]/1)+Cyanocobalamin(12 ug/1)+DL-alpha tocopheryl acetate(30 mg/1)+Folic acid(1 mg/1)+氧化镁(25 mg/1)+Nicotinamide(20 mg/1)+Omega-3 fatty acids(440 mg/1)+Pyridoxine hydrochloride(28 mg/1)+Riboflavin(4 mg/1)+Zinc oxide(26 mg/1) Kit Oral Physicians Total Care, Inc. 2010-08-24 2013-01-15 我们
Categories
- ATC Codes
- B03AB03 — Sodium feredetate
- Drug Categories
-
- Acetates
- Acids, Acyclic
- Amines
- Antianemic Preparations
- Blood and Blood Forming Organs
- Compounds used in a research, industrial, or household setting
- Diamines
- Ethylenediamines
- 铁螯合剂
- Iron Compounds
- Iron Preparations
- Iron Trivalent, Oral Preparations
- Parenteral Iron Replacement
- Polyamines
- Sequestering Agents
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as tetracarboxylic acids and derivatives. These are carboxylic acids containing exactly four carboxyl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Tetracarboxylic acids and derivatives
- Direct Parent
- Tetracarboxylic acids and derivatives
- Alternative Parents
- Alpha amino acids/Trialkylamines/Carboxylic acid salts/Amino acids/Organic transition metal salts/Carboxylic acids/Organopnictogen compounds/Organic zwitterions/Organic sodium salts/Organic oxides show 2 more
- Substituents
- Aliphatic acyclic compound/Alpha-amino acid/Alpha-amino acid or derivatives/Amine/Amino acid/Amino acid or derivatives/Carbonyl group/Carboxylic acid/Carboxylic acid salt/Hydrocarbon derivative show 14 more
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- organic sodium salt, iron chelate (CHEBI:78292)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 403J23EMFA
- CAS number
- 15708-41-5
- InChI Key
- MKWYFZFMAMBPQK-UHFFFAOYSA-J
- InChI
-
InChI=1S/C10H16N2O8.Fe.Na/c13-7(14)3-11(4-8(15)16)1-2-12(5-9(17)18)6-10(19)20;;/h1-6H2,(H,13,14)(H,15,16)(H,17,18)(H,19,20);;/q;+3;+1/p-4
- IUPAC Name
-
sodium 5-(carboxymethyl)-3,10,13-trioxo-2,11,12-trioxa-5,8lambda5-diaza-1-ferratetracyclo[6.3.3.0^{1,5}.0^{1,8}]tetradecan-5-ium-8-ylium-1,1-diuide
- SMILES
-
[Na+].[O-]C(=O)C[N+]12CC[N+]34CC(=O)O[Fe--]13(OC(=O)C2)OC(=O)C4
References
- 一般引用
- Not Available
- External Links
-
- KEGG Drug
- D07145
- ChemSpider
- 25555
- 105673
- ChEBI
- 78292
- ChEMBL
- CHEMBL1705709
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count Not Available Recruiting Treatment Craniosynostosis 1
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
-
Form Route Strength Kit Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source Water Solubility 0.0541 mg/mL ALOGPS logP 1.45 ALOGPS logP -1.5 Chemaxon logS -3.9 ALOGPS pKa (Strongest Acidic) 1.12 Chemaxon pKa (Strongest Basic) -7 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 119.03 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 71.6 m3·mol-1 Chemaxon Polarizability 26.41 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like规则 No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available
Drug created at June 23, 2017 20:40 / Updated at February 21, 2021 18:54